Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report
Authors:
Open Access
- 8 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 8, 333
Abstract
Background: Lymphoma is a common hematological malignancy with many subtypes and considerable heterogeneity. Traditional treatments include chemotherapy, radiotherapy, and surgery. Patients with relapsed, refractory or advanced stage lymphoma have a dismal prognosis. In recent years, chimeric antigen receptors (CARs) have been recognized as powerful tools that redirect antigen-specific T cells independent of human lymphocyte antigen (HLA) restriction and specifically kill tumor cells. Satisfactory results with CAR-based treatments have been achieved in relapsed/refractory B cell leukemia/lymphoma. Our center explored the strategy of subcutaneous injections combined with intravenous drip to overcome certain issues. Case presentation: A patient with stage IV refractory and relapsed diffuse large B cell lymphoma was treated with regional and intravenous CAR-T cells. During the observation period, the temperature of the skin at the abdominal wall mass was slightly elevated, and tolerable pain in the injection area was reported. Imaging showed regional liquefactive necrosis. After the sequential administration of ibrutinib and venetoclax, the abdominal wall mass significantly decreased in size. Conclusion: The regional injection of CAR-T cells might be safe and feasible for the treatment of regional lesions in patients with refractory and relapsed advanced lymphoma.Keywords
This publication has 17 references indexed in Scilit:
- Making CAR T Cells a Solid Option for Solid TumorsFrontiers in Immunology, 2018
- The application of CAR-T cell therapy in hematological malignancies: advantages and challengesActa Pharmaceutica Sinica B, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2017
- Ibrutinib treatment improves T cell number and function in CLL patientsJournal of Clinical Investigation, 2017
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaMolecular Therapy, 2017
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Antibody-modified T cells: CARs take the front seat for hematologic malignanciesBlood, 2014
- The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cellsNature, 1997